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Abstract 
Pancreatic cystic tumors have a wide range of malignant potential and it is 
therefore crucial to predict the presence of malignancy with reliable diagnostic accuracy in 
order to decide surgical indication. Although preoperative imaging and clinical findings, 
combined with cyst fluid molecular markers, have increased the diagnostic performance, 
diagnostic accuracy remains less than satisfactory. To improve the diagnostic performance 
of telomerase activity for predicting the malignancy of pancreatic cystic tumors, I 
quantified the telomerase activity using a combination of droplet digital PCR platform and 
a telomerase repeat amplification protocol (dd-TRAP). This resulted in the higher detection 
sensitivity and a wider quantifiable range compared to the conventional method. Using this 
technique, telomerase activity was measured in surgically-aspirated cyst fluid samples from 
184 patients who underwent pancreatic resection for a cystic lesion: 118 with intraductal 
papillary mucinous neoplasm, 45 with serous cystadenoma, 13 with other cystic neoplasms, 
and 8 with pseudocyst. I found telomerase activity was reduced in samples that had been 
previously thawed. Among unthawed samples, I revealed that cyst fluids with invasive 
cancer and high-grade dysplasia showed the higher telomerase activity (median 
[interquartile range], 1299 [830.2–11980] copies/µL of cyst fluid) than those without 
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counterparts (23.1 [3.3–344.8] copies/µL, P < 0.001). Cyst fluid telomerase activity >730 
copies/µL had a sensitivity of 83.3% and a specificity of 90.0% for predicting the invasive 
cancer/high-grade dysplasia. Among cysts classified preoperatively as having “worrisome 
features”, cyst fluid telomerase activity had high diagnostic performance (sensitivity, 
92.3%; specificity, 86.5%; accuracy, 88.0%). In multivariate analysis, telomerase activity 
was an independent predictive factor associated with malignancy. Absolute quantification 
of telomerase activity using the dd-TRAP assay could be a powerful diagnostic tool for 
predicting the malignancy with in a pancreatic cysts.
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Background 
 Due to the improvement and widespread use of high-resolution multimodality 
imaging, management of pancreatic cystic tumors are increasingly being acknowledged 
during the past two decades1). Pancreatic cystic tumors encompass a wide spectrum of 
malignant potential from benign to borderline to malignant1, 2). Serous cystic neoplasms 
(SCN)s are usually benign and have low potential of malignancy in nearly all the cases, and 
when asymptomatic, they can be managed by surveillance based on computed tomography 
(CT)/magnetic resonance imaging (MRI) imagining3). Mucinous cystic neoplasms (MCN)s 
should be resected without any surveillance because of their malignant potential4). Solid 
pseudopapillary neoplasms (SPN)s are also recommended to be resected at the time of 
diagnosis5). Intraductal papillary mucinous neoplasms (IPMN)s have a wide spectrum of 
pathological malignancy ranging from low-grade dysplasia (LGD) to invasive cancer. Only 
high-grade dysplasia (HGD) and invasive cancer should be resected and LGD and 
intermediate grade dysplasia (IGD) should be managed by surveillance4).  
  Currently, differential diagnosis and surgical indication of pancreatic cystic 
tumors is based on the clinical symptoms and imaging findings. For predicting the possible 
presence of malignancy and surgical indication, the International Consensus Guidelines 
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(ICG) 2012 has stratified the specific clinical and imaging findings based on CT/MRI into 
“worrisome features” and “high-risk stigmata”4). In accordance with the diagnostic 
algorithm, surgical intervention is recommended for cases with “high-risk stigmata” while 
only the cases with “worrisome features” should undergo the endoscopic ultrasonography 
(EUS) analysis for further evaluation. In addition to the imaging findings, EUS-guided cyst 
fluid cytology and biomarker analysis have been utilized for the differential diagnosis of 
pancreatic cystic tumors6). Both cytology and carcinoembryonic antigen (CEA) analysis 
using EUS with fine-needle aspiration (EUS-FNA) are highly specific (95.0% and 83.0%, 
respectively)7); however, these analyses show false-negative results (33.0% for cytology 
and 7.7% for CEA) mainly because of sampling errors8, 9). Therefore, novel biomarkers 
with higher diagnostic accuracy are urgently needed. 
   Telomerase is a key enzyme in the immortalization of malignant neoplasms and 
its elevated activity has been detected in various human cancers including pancreatic 
cancer10, 11). Previous reports investigating pancreatic juice samples have demonstrated the 
diagnostic utility of telomerase activity for differentiating the pancreatic cancers from 
benign pancreatic tumors with high sensitivity and specificity12-14). Furthermore, recent 
meta-analysis revealed that the telomerase activity measurement in pancreatic juice sample 
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showed the higher diagnostic performance than the four major genetic marker (KRAS, 
CDKN2A/p16, TP53, and SMAD4/DPC4) for the differential diagnosis of pancreatic 
cancer15). As for the pancreatic cystic tumors, Hashimoto et al. showed the higher 
telomerase activities in invasive cancer tissue arising from IPMN and HGD than in either 
IGD or those in LGD IPMN16). Furthermore, telomerase activity in solid components and 
thickened walls of pancreatic cystic lesions obtained by imaging-guided biopsies was 
higher in malignant tumors than in benign tumors and pancreatic pseudocysts17). However, 
telomerase activity measurements in these studies were based on the tissue samples, and no 
previous reports have evaluated telomerase activity using bulk aspirated cyst fluid samples. 
 The most common method used to measure the telomerase activity is the 
telomerase repeat amplification protocol (TRAP) assay, developed in 199418). Briefly, this 
assay involves three steps. First, endogenous telomerase in cell or tissue extracts extends 
the synthesized oligonucleotide with telomeric repeats. Next, these extended products are 
specifically amplified by PCR using upstream and downstream primers. Finally, 
electrophoresis and subsequent densitometries for PCR products are conducted to measure 
telomerase activity as a ratio of the internal control18). Even though the improvement of this 
method with some modification, this method need laborious polyacrylamide gel 
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electrophoresis and subsequent densitometric analysis of 6-bp telomeric ladder19-21). 
Moreover, because of the non-quantitative and relative activity measurement compared 
with that of the reference sample, at least ~ 2-fold difference of telomerase activity can be 
detectable on the basis of this conventional gel-based TRAP assay (gel-TRAP assay)20, 22). 
Taken together, further improvements are required to apply high-throughput measurement 
without multiple experimental steps and reference samples in each reaction. 
Droplet digital PCR (ddPCR), a recently developed technique, involves 
emulsification and PCR amplification inside the thousands of nanolitter scale droplets, each 
droplet containing one or no molecules of target DNA23-25). Simple, precise, and 
reproducible absolute quantification of the number of target DNA can be conducted by 
counting the number of positive droplets at the endpoint PCR thermocycling without the 
need of a standard curved or the consideration of the amplification rate. Recently, Ludlow 
et al. applied ddPCR with EvaGreen double strand DNA binding dye to the second step of 
the TRAP assay and compared the performance in terms of diagnostic resolution, 
quantifiable range, and reproducibility between the conventional gel-TRAP assay and the 
newly developed ddPCR-based TRAP (dd-TRAP) assay in various types of culture cells26). 
They revealed that dd-TRAP assay exhibits greater precision, better reproducibility and a 
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wider detectable ranges compared to the gel-TRAP assay26). These results suggest that the 
dd-TRAP strategy can be applied for high-throughput analyses of clinical samples.
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Aim 
In the present study, to investigate the applicability and practicality of the 
dd-TRAP assay for clinical samples and increase the diagnostic performance for predicting 
the presence of malignancy within a pancreatic cyst using quantitative telomerase activity 
measurement, I applied dd-TRAP assay to surgically aspirated cyst fluid samples. 
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Materials and Methods 
Ethics 
 All elements of this study were approved by the institutional review board of 
Johns Hopkins Medical Institutions and written informed consent was obtained from all 
enrolled patients. 
 
Patients and specimens 
Patients with pancreatic cystic tumor who had undergone surgical resection at the 
Department of Surgery, Johns Hopkins Hospital between 2008 to October 2015 were 
included in this study. Patients’ characteristics, clinical symptoms, preoperative imaging 
findings such as CT, MRI, and EUS with cyst fluid cytology and CEA values were obtained 
from hospital records. I classified the imaging findings on the basis of CT/MRI into 
“high-risk stigmata”, “worrisome features”, and “low risk” following the ICG 2012 
algorism4). Details of clinical and imaging findings of each risk group are shown in Table 1. 
A cut-off value of CEA in cyst fluid was set to 192 ng/mL according to the previous 
report27). The pathology of the surgically resected tumor was reviewed by pancreatic 
pathologists. The decision to surgical resection for each case is based on multiple factors 
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including not only the potential risks of malignancy within a cyst but also the clinical 
symptoms caused by an enlarged cyst and the age, performance status, and co-morbidity of 
patient. All of cyst fluid samples were harvested from resected pancreatic cystic tumor. 
Cyst fluid samples were aspirated from the resected cyst in the surgical pathology suite 
immediately after the surgical resection using a fine needle sterile syringe and stored 
immediately at 4 °C and then transferred on ice to the laboratory generally within two hours, 
where it was aliquoted and stored at – 80 °C. All cyst fluid samples utilized in this study 
had been prospectively collected in institutional fluid and tissue bio-bank in a standardized 
fashion. All experiments and data analysis were conducted in a blinded fashion, without 
any prior knowledge of pathological diagnosis. 
 
Cell culture 
Human pancreatic cancer cell lines MiA PaCa-2, BxPC-3, Hs 766T, PANC-1, 
AsPC-1, CFPAC-1, Capan-1, Capan-2, and SU.86.86 were obtained from the American 
Type Culture Collection (Rockville, MD, USA) and A38-5 was obtained from the 
investigator who created the line [Dr. James Eshleman (Johns Hopkins University, 
Baltimore, MD, USA)]. An immortal human pancreatic duct epithelial cell line, HPDE, was 
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kindly provided by Dr Ming-Sound Tsao (University of Toronto, Ontario, Canada). All cell 
lines, except for HPDE, were cultured in Dulbecco’s modified Eagle’s medium (Life 
Technologies, Inc., Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum 
(Mediatech, Inc., Manassas, VA, USA) and 1% antibiotics (Pen/Strep; Life Technologies) 
and incubated at 37 °C in a humidified atmosphere of 5% CO2 in air. HPDE cells were 
cultured in keratinocyte serum free medium supplemented by bovine pituitary extract and 
epidermal growth factor (Life technologies).  
 
Protein extraction 
Following harvesting, I determined the original volume of cyst fluid applied to the 
analyses in accordance with the visual inspection in predicting the sufficient yield of 
protein, at least 1 µg. The average volume of cyst fluid used to isolate protein was 400 µL 
(range, 40–1,000 µL). Cells were pelleted down by centrifugation at 5,000 rpm for 5 min. 
Supernatant was aspirated and discarded. According to the previous study, precipitated cells 
were lysed in NP-40 buffer (10 mM Tris-HCl, pH 8.0, 1 mM MgCl2, 1 mM EDTA, 1% 
(vol/vol) NP-40, 0.25 mM sodium deoxycholate, 10% (vol/vol) glycerol, 150mM NaCl, 
5mM β-mercaptoethanol, 0.1mM AEBSF (4-[2-aminoethyl] benzenesulfonyl fluoride 
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hydrochloride)) for a 30 min on ice26). The lysate was then centrifuged at 15,000 rpm for 20 
min at 4 °C and the supernatant collected as the cell extract. Protein concentration was 
measured by BCA method using Pierce BCA Protein Assay Kit − Reducing Agent 
Compatible (Thermo Fisher scientific, Waltham, MA, USA) and stored at – 80 °C until 
ready for further analyses. I repeated the protein extraction procedures by adding the equal 
volume of NP-40 lysis buffer into the remaining pellet until there was no longer any lysed 
protein detectable. For cyst fluid samples, 1 to 5 µg of protein extract (depending on the 
yield of extracted protein from the original cyst fluid) was applied to further analysis.  
 
gel-TRAP assay 
The first step for TRAP assay is the extension reaction. In brief, endogenous 
telomerase in cell extracts can catalyze addition of varying numbers of TTAGGG 
hexameric repeats onto the 3’ end of a telomeric TS primer20, 26). One µg of protein extracts 
from cell line pellets were applied and incubated with 50 µL of extension reaction mixture 
containing 1 × TRAP reaction buffer (10 × concentration: 200 nM Tris-HCl, pH 8.3, 15nM 
MgCl2), 0.4 mg/mL bovine serum albumin, TS primer (200 nM; 
5’-AATCCGTCGAGCAGAGTT-3’), dNTP (2.5 mM each, Thermo Fisher scientific) at 
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25 °C for 60 min.  
The second step is to amplify the extension reaction products by PCR. The total 
volume of the gel-TRAP PCR reaction mixture was 25 µL and contained 1 × 
ThermoPol® Reaction Buffer (New England Biolabs, Ipswich, MA, USA), 12.5 ng of TS 
primer, 0.125 µL of TRAP primer mix [ACX primer (5’-GCGCGGCTTACCCTTACCCCC 
TAACC-3’), NT primer (5’ATCGCTTCTCGGCCTTTT-3’), and TSNT primer 
(5’-AATCCGTCGAGCAGAGTTAAAAGGCCGAGAAGCGAT-3’)] as previously 
described21), 1 U of Taq DNA polymerase (New England Biolabs), 50 µM of each dNTP 
and 2 µL of extraction reaction mixture (i.e. × 0.04 dilution of cell extracts in 50 µL of 
extension reaction mixture). The PCR reaction was then started at 95°C for 5 min, followed 
by a 30 cycles of 3 steps amplification (95 °C for 30 sec, 54 °C for 30 sec, and 72 °C for 30 
sec). Following PCR, reaction mixtures were analyzed by electrophoresis in 0.5 × 
Tris-borate-EDTA buffer on 12% polyacrylamide non-denaturing gels and visualized with 
ethidium bromide staining. The images were then processed and quantified by densitometry 
using ImageJ® software (National Institutes of Health, Bethesda, MD, USA). Telomerase 
activity at the ratio of the intensity of 6-bp ladder to that of internal control (IC) was 
calculated based on the following formula: ((intensity of sample’s 6-bp ladder) – 
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(background intensity between the sample lanes))/intensity of sample’s IC band21). The 
experimental workflow of the gel-TRAP assay is shown in Figure 1. 
 
Droplet digital TRAP assay 
For ddPCR, each 20 µL reaction setup contained 1 × ddPCR EvaGreen Supermix 
(Bio-Rad, Hercules, CA, USA), 50 nM of TS and ACX primer, 2 µL of extension reaction 
mixture (the same as for the gel-TRAP assay described above). The 20 µL droplet ddPCR 
reaction mixture was then loaded into the DG8 disposable droplet generator cartridge 
(Bio-Rad). A volume of 70 µL of droplet generation oil was loaded into the oil well for 
each sample. The cartridge was placed into the Droplet Generator QX200 (Bio-Rad). This 
draws both the PCR reagents and oil through a flow-focusing nozzle where around 20,000 
individual droplets ~1 nL in size are formed, suspended in an emulsion. Following droplet 
generation, the water-in-oil droplet emulsions were transferred to a 96-well polypropylene 
PCR plate (twin.tec PCR plate; Eppendorf, Hauppauge, NY, USA). The plate was 
heat-sealed with foil using a PX1 PCR Plate Sealer (Bio-Rad) and placed in a Veriti 
Thermal Cycler (Applied Biosystems). Thermal-cycling conditions were 95°C for 5 
minutes (1 cycle), was followed by 37 cycles of 95 °C for 30 sec, 54 °C for 30 sec, 72 °C 
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for 30 sec. A dye-stabilization step was also included at the end of thermal cycling protocol 
(4 °C for 5 min then, 95 °C for 5 min, and finally at 12 °C indefinite hold). The temperature 
ramp rate was set to 2.5 °C/sec, and the lid was heated to 105 °C, according to the 
manufacture’s recommendations. After the thermal cycling, droplet reading was performed 
on a QX200 ddPCR Droplet Reader (Bio-Rad), which automatically reads the droplets from 
each well of the plate. Analysis was done using QuantaSoft 1.7.4 Analysis software 
(Bio-Rad) and the target concentration (copies/µL; PCR scale) was then computed using 
Poisson statistics. Figure 1 shows the study workflow of the dd-TRAP assay and the 
conventional gel-TRAP assay. In the present study, to best reflect the nature of original cyst 
fluid, absolute quantification of telomerase products per microliter of original cyst fluid 
was calculated using the following formula: telomerase product (copies)/PCR volume (20 
µL) × PCR volume (20 µL)/extracts applied to PCR (µg) × total yield of protein extracts 
(µg)/ original cyst fluid volume (µL).  
 
Optimization of dd-TRAP assay for absolute quantification 
 I attempt to estimate the limit of detection (LOD) in accordance with the previous 
reports28, 29). To determine the limit of blank (LOB) of telomerase activity using dd-TRAP 
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assay, I first performed the 60 replicates of ddPCR with 5 technical replicates using the 12 
different extraction reaction mixtures containing only NP-40 lysis buffer as blank samples. 
Sample processing of mixtures was performed on	 several different days considering the 
consistency across the study periods. Pooled data were assumed to follow a Gaussian 
distribution. When α = 0.05, the LOB is estimated by the 95th percentile of the distribution 
of the blank samples.  
𝐿𝑂𝐵 = 𝑀! + 1.645×𝑆𝐷! 
where Mb stands for the mean of blank sample data and SDb for the combined standard 
deviation (SD) of the blank sample data. I next performed ddPCR with 20 replicates in each 
2 extract with different low concentration of 0.0008 µg and 0.00032 µg, respectively. When 
β = 0.05, the LOD is estimated by the 95th percentile of the distribution of the low 
concentration samples. LOD estimate can be expressed in a following formula as 
𝐿𝑂𝐷   =   𝐿𝑂𝐵 + 𝑐!×𝑆𝐷! 
where SDs stand for the combined SD of the low concentration sample data and 𝑐!, the 
multiplicative factor that is associated with the target acceptable error risk of false negative, 
is calculated as follows: 
𝑐𝛽   = 1.6451− 14 𝑁𝑠 − 𝜅  
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where Ns means the total number of replicates and κ means the number of samples. 
According to the estimated LOD, the actual copies above LOD considered to be 
quantifiable. In the present study, I used a half value between LOB and LOD for the actual 
values between them. For the actual value below LOB, I used as “zero”.  
  
Statistics 
The non-parametric Wilcoxon signed-rank test was used to compare continuous 
variables. The chi-square test was used to compare categorical variables. Correlations 
between two different variables were assessed by scatter-plot and R2 value. The diagnostic 
accuracy of telomerase activity in predicting the presence of malignancy was assessed by 
receiver operating characteristics (ROC) curve analysis. The cut-off value was defined as 
the result with the highest sensitivity and specificity that lay closest to the left upper corner 
of the curve. A multivariate analysis using the logistic regression model was performed 
including the variables with significant by univariate analysis. Statistical analysis was 
performed using the JMP Pro 11.0.0 statistical software (SAS Institute Inc., Cary, NC, 
USA) and GraphPad Prism V6.0 (GraphPad Software, San Diego, CA, USA). P-value of 
less than 0.05 was considered to indicate statistical significance. 
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Results 
dd-TRAP assay using pancreatic cancer cells lines 
 First, I detected telomerase activity by the dd-TRAP assay using pancreatic 
cancer cell lines. Figure 2A shows a representative result of the dd-TRAP assay using 2 of 
the 50 µL the extension reaction mixtures (i.e. 0.04 of 1 µg cell extracts) derived from the 
MiA PaCa-2 cell line with negative controls. As negative controls, cell extracts were treated 
with RNase A (37 °C for 20 min) or with heat (95 °C for 5 min) and then applied to PCR 
reaction. Both the RNase A pre-treatment and heat inactivation drastically decreased the 
number of signals. Considering the evidences that the PCR products amplified by the TRAP 
assay contains multiple size of amplicons known as 6-bp ladder, I set a manual threshold 
above the negative cluster in 1-D plot in each well. Figure 2B shows the actual accepted 
total droplets in each lane (16,000–18,000 droplets), indicating successful droplet 
generation in the dd-TRAP method, which contained diluted cell extracts. Figure 2C shows 
the concentration of telomerase products corresponding to Figure 2A after the 
computational analysis using Poisson statistics. I extracted the DNA from the droplets after 
the PCR reaction and analyzed the size of amplicons by electrophoresis on a 
polyacrylamide gel and it was detectable that 6p-ladder as telomerase product. The image 
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was similar to conventional gel-TRAP assay (Figure 2D).  
 
Linearity and limit of detection of the dd-TRAP compared to the gel-TRAP assay 
 In order to investigate the diagnostic utility of the dd-TRAP assay in terms of the 
wider detectable range and higher detection sensitivity than the gel-TRAP assay, I 
compared the telomerase activity between the dd-TRAP and the gel-TRAP assay using the 
serial dilution of MiA PaCa-2 cell extracts. Figure 3A and 3B shows the result of 
electrophoresis and subsequent densitometry of the gel-TRAP assay, where I could not 
detect the 6-bp ladder in lanes containing 4 ng or less of the applied cell extracts. 
Furthermore, relative intensities were saturated in lanes containing 500 ng or more. 
Therefore, I estimated that the dynamic range of measurement for relative intensity was 
from 8 ng to 500 ng of cell extract. On the contrary, the dd-TRAP assay detected 
telomerase activity in lanes containing 0.32 ng to 2,500 ng of cell extract (Figure 3C and 
3D). To ensure the robust quantification within a low concentration range, I attempted to 
determine the LOD. Figure 3E shows the LOD value for telomerase activity based on 
dd-TRAP is 0.468 (telomerase products/µL; PCR scale). Based on the LOD, the dynamic 
quantifiable range of the dd-TRAP technique is from 2,500 ng of applied cell extracts 
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(1,734 copies/µL) to 0.8 ng (0.59 copies/µL) with high linearity (R2 = 0.99657), indicating 
a wider range and higher linearity compared to the gel-TRAP assay (Figure 3F).    
 
Comparison of dd-TRAP to gel-TRAP assay using pancreatic cancer cell lines 
 It is known that the pancreatic cancer cells demonstrate the various degrees of 
telomerase activity, partially depending on the cell growth and aggressiveness30). I 
measured telomerase activities in 10 pancreatic cancer cell lines and one immortalized 
pancreatic ductal epithelial cell line (HPDE). Figure 4A and 4B shows the actual telomerase 
activities using the gel-TRAP and dd-TRAP assays, respectively. Notably, previous results 
reported by the HPDE established group revealed that the HPDE cell line had considerable 
telomerase activity31), which is consistent with the present results (Figure 4B and 4C). To 
ensure the consistency of telomerase activity measurement between the dd-TRAP and 
gel-TRAP assays, I compared the relative telomerase activity, using levels of MIA PaCa-2 
cells as a reference. Figure 4D shows a positive correlation (R2 = 0.91498) between the two 
different assays, but the dd-TRAP assay demonstrates a wider range of detection than the 
gel-TRAP. Taken together, dd-TRAP is more sensitive and linear and has a wider range of 
detection than gel-TRAP. 
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Patient population 
 A total of 202 cyst fluid samples were initially collected, but I excluded 18 cases 
for the reasons shown in Figure 5. Therefore, the cohort of the present study consisted of 
184 patients (Figure 5). The characteristics of all included patients are shown in Table 2. 
There were 118 patients with IPMN, 12 with MCN, 45 with SCN, 8 with a pseudocyst, and 
1 with a pancreatic neuroendocrine tumor (PanNET). To assess the influence of protein 
integrity on overall results, I then stratified samples into subgroups according to the 
freeze/thaw repeats and the length of sample storage.  
 
Absolute quantification of telomerase activity in pancreatic cystic fluid 
As shown in Table 2, cyst fluid samples were heterogeneous across the specimens 
in terms of the volume, appearance, and color, and it was hypothesized that this 
heterogeneity might affect the efficiency of protein lysis processing and the subsequent 
results of the analysis. Actually, the median and range of the original volume of cyst fluid 
used for the analysis was 400 (40–1,000) µL, and the median concentration of cell extract 
after the first lysis processing was 1.23 µg/µL. To verify the validity of the telomerase 
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activity measurement per original cyst fluid samples, I investigated and analyzed the 
feasibility of the dd-TRAP assay using pancreatic cyst fluid samples regarding the 
following points. First, Figure 6A shows the total yield of protein from MiA PaCa-2 cells, 
lysed into NP-40 buffer at different concentrations. Irrespective of lysed concentration, 
there were no remaining proteins in the pellet of MiA PaCa-2 cells after three repeats of 
lysis processing. As for the 184 clinical cyst fluid samples, the repeat number for lysis 
processing varied across the samples ranging from one to seven repeats, to accomplish 
complete protein extraction (Figure 6B). Overall, complete protein extraction could be 
obtained within three repeats for 87% of all samples. I next measured the cell-free 
telomerase activity in the supernatant of cyst fluid and ensured that it was negligible 
compared with that in whole cell extracts derived from precipitates (Figure 7). I then 
investigated and analyzed the linear correlation between the loading cell extracts and 
detectable telomerase products per PCR scale. Figure 8 shows the linear correlation 
between the amount of cell extracts applied to the analysis and telomerase products. Finally, 
to investigate the inter-day reproducibility, I repeated the experiments on four different 
days. The day before day 1, I divided the sample into four aliquots for each experimental 
day. On each day, I performed the protein extraction from aliquots and the subsequent 
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analytic procedures independently. Figure 9 shows the reproducibility of similar results 
across replicates (coefficient of variation ~ 20%). These results suggest that the telomerase 
product copies per microliter of original cyst fluid as a unit of absolute quantification are 
acceptable. 
 
Stratification of cyst fluid samples according to the protein integrity 
 Since the dd-TRAP assay measures enzymatic activity and therefore needs 
samples of optimal quality, I determined if cyst telomerase activity was affected by length 
of storage at –80 °C or by the effects of freeze/thawing (some samples from each diagnostic 
group had previously undergone one or more freeze/thaws) (Table 3). I found evidence that 
prior freeze/thawing, but not length of storage, was associated with reduced telomerase 
activity (Figure 10). Therefore, to the best reflect of robust measurement of telomerase 
activity, I performed the further analysis focusing on the unthawed samples from 84 
patients. Table 4 shows the characteristics of these 84 patients whose samples had not 
undergone prior freeze/thawing. 
 
Diagnostic performance of the telomerase activity in pancreatic cyst fluid 
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 Among these 84 patients, higher levels of telomerase activity were detected in the 
cyst fluid of IPMN cases with HGD compared to IPMN cases with IGD, cases with SCN, or 
cases with a pseudocyst (P < 0.001, Figure 11A). I also compared cyst fluid telomerase 
activity in the most relevant diagnostic groups: cases with IPMN and HGD +/- an 
associated invasive cancer vs. those with IPMN and either IGD or LGD (P < 0.001), and vs. 
SCN (P < 0.022), respectively (Figure 11B). There was no significant difference in 
telomerase activity between cyst fluids from IPMNs with an associated invasive cancer and 
those from IPMNs with HGD only (P = 0.280, Figure 11A). The median value and 
interquartile range of telomerase activity levels in each group are shown in Figure 11C. 
Among all 84 cases, the telomerase activity level (cut-off value: 730 copies/µL of cyst 
fluid) with the best overall accuracy for distinguishing cyst fluids with invasive 
cancer/HGD vs. those from IGD/LGD had an area under the curve (AUC) of 0.890; for the 
58 IPMN cases the AUC was 0.853 (Figure 11D and 11E, respectively). In this series, 
telomerase activity had higher diagnostic sensitivity (83.3%) than other clinical parameters 
for distinguishing IPMNs with invasive cancer or HGD from IPMNs with lower grade 
dysplasia (Table 5). 
 I also evaluated the diagnostic accuracy of telomerase activity in the cases whose 
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cyst fluid samples had undergone multiple (2 or 3) rounds of thawing and re-freezing and 
found that the differences in telomerase activity between the IPMN invasive cancer/HGD 
group versus the IPMN IGD/LGD group were still statistically significant and had similar 
diagnostic accuracy (Figure 12). Additionally, the diagnostic performance of cyst fluid 
telomerase activity for whole study population, analyzed without regard for sample thawing, 
was very similar to the subset of cyst fluid samples without multiple freeze/thaws. 
Telomerase activity was significantly higher in the IPMN invasive cancer /HGD cases 
compared to IPMN cases with IGD, cases with LGD, and cases with SCN, and the 
diagnostic accuracy was only slightly less (AUC 0.832 for IPMN cancer /HGD vs. IPMN 
IGD/LGD) (Figure 13). The diagnostic accuracy of telomerase activity was not increased 
significantly by combining this measurement with other clinical parameters (Table 6).  
SCN samples showed the low telomerase activity irrespective of freeze/thaw 
repeats, and ranged from 0–294.4 copies/µL of cyst fluid. It is well known that the blood 
cells such as lymphocytes have low telomerase activity and there is a possibility that a 
bloody sample might demonstrate higher telomerase activity. Since some SCN cyst fluid 
samples are bloody, and since there is modest levels of telomerase activity in inflammatory 
cells, I also investigated if bloody cyst fluid samples from SCN cases had higher telomerase 
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measurements. I did find that SCN cyst fluid samples with a bloody appearance had slightly 
higher levels of telomerase activity than those with a serosanguinous or clear appearance 
(Figure 14). 
 
Predictive factors of malignancy for pancreatic cystic tumors 
Among 84 samples without prior freeze/thawing, I performed univariate analysis 
and found five significant factors predicting the malignancy: mucinous cystic fluid 
appearance (P < 0.0001), a main pancreatic duct (MPD) size larger than 5 mm (P < 0.0001), 
the presence of MPD communication (P = 0.0004), presence of mural nodule (P = 0.0093), 
and telomerase activity above 730 copies/µL of original cyst fluid (P < 0.0001) (Table 7). 
Furthermore, only telomerase activity was an independent malignant predictor in the 
subsequent multivariate analysis (odds ratio: 41.488, 95% confidence interval: 4.897–
992.730, P = 0.0002, Table 7). 
 
Subgroup analysis stratified according to the preoperative risk group 
To evaluate the diagnostic accuracy of cyst fluid telomerase activity 
measurements in relation to the pre-operative evaluation of patients, I classified the study 
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population by their clinical features into those with “high-risk stigmata”,“worrisome 
features”, and “low risk” as defined by the ICG 20124). Among the 84 cases, 11 (57.9%) of 
19 cases with “high-risk stigmata” and 13 (26.0%) of 50 cases with “worrisome features” 
had invasive cancer or HGD (Figure 15). Among the 50 cases with “worrisome features”, 
telomerase measurements had a diagnostic sensitivity of 92.3% for distinguishing those 
with invasive cancer or HGD from those with lower grades of dysplasia (Cut off: 730 
copies/µL of original cyst fluid) and an AUC of 0.927 (Table 8). Among the 58 IPMN cases, 
31 had worrisome features, and telomerase activity in this group had a similarly high 
diagnostic performance (AUC of 0.876) for distinguishing those with invasive cancer or 
HGD from those with lower grades of dysplasia (Cut off: 730 copies/µL). 
 
Telomerase activity in endoscopically aspirated cyst fluid 
 To evaluate the utility of telomerase activity measurement for preoperative 
diagnosis, I compared the telomerase activities in endoscopically aspirated cyst fluid 
samples with those in matched surgically aspirated samples. Although statistical analysis 
could not be performed because of the small sample size, telomerase activity in both 
endoscopically and surgically aspirated cyst fluid from the case of IPMN with HGD was 
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the highest among the three matched three cases (Table 9). Similar values for telomerase 
activity were measured between the endoscopically and surgically aspirated cyst fluid 
samples in cases No. 1 and 2. However, telomerase activity was much higher in the 
surgically aspirated cyst fluid than that in the endoscopically aspirated samples in case No. 
3 of IPMN with HGD (Table 9). 
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Discussion 
 In the present study, I conducted absolute quantification of telomerase activity 
using the dd-TRAP assay, which showed powerful diagnostic performance for the presence 
of malignancy within a pancreatic cyst. The present study is the first report with regard to 
two notable findings. First, combining the TRAP assay with the ddPCR method, namely the 
dd-TRAP assay, is applicable and practical for clinical samples. Second, telomerase activity 
measurement in pancreatic cyst fluid samples is useful for predicting malignancy of 
pancreatic cystic tumors. 
    Ludlow AT, et al. first developed the dd-TRAP assay and demonstrated the 
linearity and reproducibility of quantification of telomerase activity from a variety of cell 
types such as tissue culture cells and primary adult human cells26). Although the gel-TRAP 
assay was well established and widely used, and still remains to be sufficient for the 
qualitative or semi-quantitative measurement of telomerase activity, the utility of this 
method for clinical samples is considered not be feasible. Using the conventional gel-TRAP 
assay, telomerase activity was measured as relative values for internal controls and/or 
reference samples, meaning that there is a lack of precise quantification. Furthermore, 
polyacrylamide gel electrophoresis and subsequent gel staining or autoradiography steps 
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are required to visualize the 6-bp ladder and to quantify telomerase activity, which takes a 
lot of time. Recently, a real-time quantitative PCR based TRAP assay has been reported by 
several groups21, 32-35). Even though this method allows for a more quantitative analysis of 
telomerase activity rather than the gel-TRAP method, data analysis regarding setting of an 
amplification threshold and quantifiable range of Ct value remains debatable34, 35). In 
contrast, the dd-TRAP assay allows for the precise quantification of telomerase activity and 
needs neither standard samples, internal controls, nor electrophoresis. Therefore, the 
dd-TRAP assay can be a potential diagnostic tool for high-throughput screening of 
telomerase activity using clinical samples. 
 One of the most important analytical processes for the ddPCR platform was to set 
the exact position of the threshold value for distinguishing the positive from negative 
droplets. Despite the simplicity of the principle that positive droplets derived from 
amplified PCR products with intercalating dye have higher fluorescence amplitude than the 
negative droplets without PCR products, there is no well-established method for how to set 
an exact threshold line especially in samples with intermediate signals between positive and 
negative clusters36). Apart from the usual PCR assay, the TRAP assay has unique 
characteristics since it contains multiple amplicon sizes, depending on telomerase activity. 
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Actually, greater numbers of EvaGreen molecules are capable of binding to larger 
amplicons, meaning that higher fluorescence amplitude is observed in longer PCR products 
than in shorter ones37). In the present study, as shown by Ludlow AT et al., the dd-TRAP 
assay produced a considerable number of intermediate signals where no clear 
discrimination was observed between positive and negative droplets. Negative control 
samples with RNase A treatment and heat inactivation abolished the almost all the positive 
and intermediate signals. Furthermore, for an unknown reason, a shift in the baseline as 
negative droplet cluster in 1-D plot across samples was observed. Taken together, 
intermediate signals between the positive and negative cluster of droplets were considered 
as “positive”. For the present analysis, I manually set the threshold line just above the 
negative clusters by visual interpretation, which was shown to be a reliable method for 
analysis.  
Another important note about the data interpretation and analysis is the rate of 
false positive. Since the development of the TRAP assay, the efforts to reduce primer dimer 
formation have been attempted, because the TRAP assay is usually based on the 
amplification of telomeric repeats using fixed primer pairs18). Previous reports developed 
the ACX primer, having a 6 bp anchor at the 5’-end and a new permutation of the telomeric 
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sequence, resulted in the significant reduction of primer dimer formation20). However, as 
shown in previous reports, the present study revealed that very minor background signals 
were observed in non-template controls26), partially because of high detection sensitivity of 
the ddPCR platform. To assess the robustness of detection and quantification, I determined 
the LOB and LOD prior to clinical sample analysis. Actually, LOB was estimated to be 
0.153 copies/µL of PCR scale and these very minor background signals might be derived 
from the multiple factors of non-specific amplicon, primer-dimer formation, and incidental 
contamination of exogenous protein. 
 For the clinical specimen, to best reflect the nature of original cyst fluid, absolute 
quantification of telomerase products per microliter of original cyst fluid was calculated 
and applied to further analysis following the formula described in Materials and Methods. 
Actually, the actual amount of cell extracts applied to the extension reaction mixture varied 
across the specimens ranging from 1.0–5.0 µg, because part of the cyst fluid samples with 
lower cellularity contained very low amounts of protein. Moreover, telomerase activity 
derived from non-cancerous cells such as lymphocytes should be considered, especially in 
cases with precipitates containing a large number of blood cells. In these cases, there is a 
possibility that a large population of blood cells with low telomerase activity might mask 
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the cancer cell-derived telomerase activity. Therefore, quantification of telomerase products 
per microgram of cell extract might introduce bias caused by the condensation of original 
cyst fluid cellularity and might overestimate telomerase activity. Consequently, I believe 
the cellularity within original cyst fluid should be maintained in the analysis. In fact, I 
demonstrated complete protein extraction, no telomerase activity in cell-free protein, and 
linear correlation between loading amount of extracted protein and telomerase products. 
Taking these results together, the present study revealed that the absolute quantification of 
telomerase activity per microliter of original cyst fluid volume is acceptable. 
 According to the comments of ICG 2012, a combination of the clinical, imaging, 
and molecular characteristics provides the best initial preoperative diagnosis of the cyst 
type. If the EUS is available, consideration may be given for EUS with cytopathology, CEA, 
and molecular analyses. Apart from the analyses of cyst fluid cytology and CEA 
measurement, both of which have some limitations with low diagnostic sensitivity, the 
molecular and genetic biomarkers in cyst fluid are useful for predicting the biological 
behavior of pancreatic cystic tumors38-41). Recent genetic analyses revealed the specific 
features of gene alteration in each type of cystic tumors, including IPMN, MCN, SCN, and 
SPN. Springer A, et al revealed that the mutations in GNAS and KRAS were detected in 
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58 % and 78% of cyst fluid specimens from IPMN cases42), similar to 66% and 81% of 
tissue specimens, respectively43). In contrast, no GNAS mutations were present in other cyst 
types. Furthermore, using the cyst fluid samples, VHL mutation was detected in 42% of 
SCN. CTNNB1 mutation was detected in all 10 SPN cases. The authors performed the 
composite molecular and clinical markers and demonstrated a higher diagnostic accuracy 
regarding the classification of pancreatic cystic tumor types with high sensitivity (90–
100%) and specificity (98–100%)42). However, it remains unknown whether these 
molecular markers combined with the clinical or imaging findings would be useful for 
differentiating malignant pancreatic cystic tumors from benign ones. Apart from the genetic 
markers in cyst fluid, Maker AV, et al demonstrated the pro-inflammatory cytokine of 
interleukin-1β could be a potential microenvironment marker predicting malignant IPMN 
with 79% sensitivity, 95% specificity, and 0.92 of AUC44). However, it should be noted that 
the authors concluded the necessity of further validation studies because of a small sample 
size (n = 40). The present study presents a unique diagnostic approach that relies on the 
measurement of telomerase enzyme activity using protein lysate derived from cyst fluid 
precipitates. Compared to a previous report showing the usefulness of semi-quantification 
of telomerase activity from tissue specimens of pancreatic cystic tumors17), the present 
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study was distinguishable and notable in terms of the robust absolute quantification of 
telomerase activity and the usage of aspirated cyst fluid samples. Taken together, absolute 
quantification of cyst fluid telomerase activity measurement using dd-TRAP assay can be a 
potential molecular marker for predicting malignant pancreatic cystic tumors along with 
imaging features, cyst fluid cytology, and cyst fluid CEA measurement.  
I revealed that telomerase activity could be quantifiable at a very low 
concentration from pancreatic cancer MIA PaCa-2 cells, 0.0008 µg (= 0.8 ng). For clinical 
cyst fluid specimens, at least 0.04 µg in cell extracts as ddPCR template (equivalent to 1.0 
µg in extracts for extension reaction template) could be quantifiable. Considering that the 
median concentration of cell extracts after the first lysis was 1.23 µg/µL, further reduction 
of the original cyst fluid volume would be possible. Usage of large amounts of cyst fluid for 
analysis can be problematic, and further analysis is needed to determine the minimum and 
proper amount of loading samples. 
In the present study, I also demonstrated that a higher diagnostic performance of 
telomerase activity was shown, especially in cases within the “worrisome features” 
subgroup. According to the ICG 2012, EUS-guided cyst fluid analysis should be considered 
after the initial assessment of CT/MRI only in cases with “worrisome features”. Cases with 
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“high-risk stigmata” should undergo surgical resection without further examination4). 
Therefore, as shown in this study, the higher diagnostic performance of telomerase activity 
in cases with “worrisome features” would be reasonable and preferable. One possible 
explanation as to why the cases with “high-risk stigmata” showed a lower diagnostic 
accuracy could be because about half of cases with “high-risk stigmata” were diagnosed as 
invasive cancer derived from IPMN. Pancreatic cysts associated with invasive cancer would 
be formed as a result of degeneration of the tumor due to a lack of blood supply and 
subsequent hypoxic condition. Otherwise, the accessory retention cysts would be formed 
nearby the invasive cancer due to a complete obstruction of branch pancreatic duct and 
accumulation of necrotic tissue of pancreatic parenchyma45). These cysts contain a large 
amount of necrotic tissue, rather than mucus, and might affect the results of analysis. 
Alternatively, 10–15% of human cancers, including pancreatic cancer lack detectable 
telomerase activity, and maintain their telomere length in a telomerase-independent 
manner46).  
Although the number of cases was limited, I measured the telomerase activities in 
endoscopically aspirated cyst fluid samples at the time of preoperative EUS-FNA and 
compared the surgically aspirated cyst fluid samples from the three matched cases. In one 
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case of IPMN with HGD, telomerase activity in the surgically aspirated sample was much 
higher than that in the endoscopically aspirated sample. This discrepancy may be derived 
from the difference in sampling methods, such as the use of different needle sizes and 
aspiration pressures rather than tumor progression from the preoperative EUS examination 
to surgical resection. Furthermore, needle size and aspiration pressure may be problematic, 
particularly in cases with mucinous samples. Although further improvements in harvesting 
devices and procedures are required to reduce sampling error, cyst fluid telomerase activity 
in the endoscopically aspirated cyst fluid samples is promising for providing helpful 
information related to surgical indication. 
 The present study has some limitations. I used 184 surgically aspirated cyst fluid 
samples and 3 endoscopically aspirated samples because almost all EUS-guided 
endoscopically aspirated cyst fluid samples had no histological confirmation. Although all 
enrolled patients in this study underwent surgical resection and therefore had defined 
histology, the results of analyses cannot be directly applied to patients who undergo 
surveillance without surgical resection. In the future, analysis of paired fluid samples 
collected from pre-operative EUS-guided aspiration and surgery with larger sample size is 
warranted to demonstrate that there is similar telomerase activity between them. 
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Furthermore, serially collected samples from same individual who underwent surveillance 
should be assessed to demonstrate the diagnostic utility for surgical indication. 
 Another possible limitation is the inconsistency of protein integrity in the enrolled 
samples. In the present study, previous thawing/re-freezing of the cyst fluid vials resulted in 
underestimation of telomerase activity, particularly in IPMN cases; therefore, all 184 
samples were stratified according to the presence or absence of previous 
thawing/re-freezing. Protein integrity may also be affected by the sample collection, 
transportation, and dispensing steps. In the future, for sample dispensing into a large 
number of small vials containing protease inhibitor, a standard protocol for sample 
processing steps should be established to maintain protein integrity across clinical samples.
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Conclusions 
In conclusion, the present translational research study revealed the applicability 
and practicality of combining the TRAP assay with ddPCR for clinical samples. 
Furthermore, absolute quantification of telomerase activity measurement using dd-TRAP 
assay in pancreatic cyst fluid samples has potential as a predictive factor for the presence of 
malignancy within a cyst, and has a powerful diagnostic performance with high sensitivity 
and specificity compared with other clinical and imaging findings. This diagnostic accuracy 
was the most remarkable in cases within the “worrisome features” risk group. A further 
study with a large cohort, including both endoscopically and surgically collected cyst fluid 
samples, is warranted to confirm the validity of the present results and to elucidate 
dd-TRAPs usefulness for the surveillance and risk stratification of patients undergoing 
pancreatic screening. 
  43 
Acknowledgements 
 Most of all, I am tremendously grateful to my advisor and mentor, Dr. Michael 
Goggins (Departments of Pathology, The Sol Goldman Pancreatic Cancer Research Center, 
Johns Hopkins Medical Institutions). His scientific curiosity inspired me to pursue my 
doctoral degree. He provided me the freedom and opportunity to work on various research 
project with world experts in pathology. He always had an open door and was willing to 
discuss any scientific topics. He is an excellent scientist and clinician and a trusted 
colleague. I thank him for his encouragement and his kindness. 
I would like to thank all of present members of the Goggins lab. I especially thank 
Marco Dal Molin, Jun Yu, and Masaya Suenaga. Without their assistance with cell biology 
techniques and providing the many clinical samples, this work would not have been 
possible. 
I would like to thank Prof. Michiaki Unno (Department of Surgery, Tohoku 
University Graduate School of Medicine) and Prof. Akira Horii (Department of Molecular 
pathology, Tohoku University Graduate School of Medicine) for providing me to a chance 
to go abroad for research. They also gave me wise career advise and generously offered to 
help in any way that would allow me to pursue my career goals. 
  44 
 I would like to thank all of members of Department of Surgery, Tohoku 
University Graduate School of Medicine. They provided various supports and assistances 
for my focusing on my projects.  
  
  45 
References 
 
1. Brugge WR: Diagnosis and management of cystic lesions of the pancreas. J 
Gastrointest Oncol 2015; 6: 375-388. 
2. Lennon AM, Wolfgang CL, Canto MI, et al: The early detection of pancreatic 
cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Cancer 
Res 2014; 74: 3381-3389. 
3. Jais B, Rebours V, Malleo G, et al: Serous cystic neoplasm of the pancreas: a 
multinational study of 2622 patients under the auspices of the International 
Association of Pancreatology and European Pancreatic Club (European Study Group 
on Cystic Tumors of the Pancreas). Gut 2015. 
4. Tanaka M, Fernandez-del Castillo C, Adsay V, et al: International consensus 
guidelines 2012 for the management of IPMN and MCN of the pancreas. 
Pancreatology 2012; 12: 183-197. 
5. Law JK, Ahmed A, Singh VK, et al: A systematic review of solid-pseudopapillary 
neoplasms: are these rare lesions? Pancreas 2014; 43: 331-337. 
6. Maker AV, Carrara S, Jamieson NB, et al: Cyst fluid biomarkers for intraductal 
papillary mucinous neoplasms of the pancreas: a critical review from the 
international expert meeting on pancreatic branch-duct-intraductal papillary 
mucinous neoplasms. J Am Coll Surg 2015; 220: 243-253. 
7. Thornton GD, McPhail MJ, Nayagam S, et al: Endoscopic ultrasound guided fine 
needle aspiration for the diagnosis of pancreatic cystic neoplasms: a meta-analysis. 
  46 
Pancreatology 2013; 13: 48-57. 
8. Woolf KM, Liang H, Sletten ZJ, et al: False-negative rate of endoscopic 
ultrasound-guided fine-needle aspiration for pancreatic solid and cystic lesions with 
matched surgical resections as the gold standard: one institution's experience. 
Cancer Cytopathol 2013; 121: 449-458. 
9. Cizginer S, Turner BG, Bilge AR, et al: Cyst fluid carcinoembryonic antigen is an 
accurate diagnostic marker of pancreatic mucinous cysts. Pancreas 2011; 40: 
1024-1028. 
10. Shay JW, Wright WE: Role of telomeres and telomerase in cancer. Semin Cancer 
Biol 2011; 21: 349-353. 
11. Balcom JHt, Keck T, Warshaw AL, et al: Telomerase activity in periampullary 
tumors correlates with aggressive malignancy. Ann Surg 2001; 234: 344-350; 
discussion 350-341. 
12. Zhou GX, Huang JF, Li ZS, et al: Detection of K-ras point mutation and telomerase 
activity during endoscopic retrograde cholangiopancreatography in diagnosis of 
pancreatic cancer. World J Gastroenterol 2004; 10: 1337-1340. 
13. Nakashima A, Murakami Y, Uemura K, et al: Usefulness of human telomerase 
reverse transcriptase in pancreatic juice as a biomarker of pancreatic malignancy. 
Pancreas 2009; 38: 527-533. 
14. Uehara H, Nakaizumi A, Iishi H, et al: In situ telomerase activity in pancreatic juice 
may discriminate pancreatic cancer from other pancreatic diseases. Pancreas 2008; 
36: 236-240. 
15. Hata T, Ishida M, Motoi F, et al: Telomerase activity in pancreatic juice 
  47 
differentiates pancreatic cancer from chronic pancreatitis: A meta-analysis. 
Pancreatology 2016. 
16. Hashimoto Y, Murakami Y, Uemura K, et al: Telomere shortening and telomerase 
expression during multistage carcinogenesis of intraductal papillary mucinous 
neoplasms of the pancreas. J Gastrointest Surg 2008; 12: 17-28; discussion 28-19. 
17. Yeh TS, Cheng AJ, Chen TC, et al: Telomerase activity is a useful marker to 
distinguish malignant pancreatic cystic tumors from benign neoplasms and 
pseudocysts. J Surg Res 1999; 87: 171-177. 
18. Kim NW, Piatyszek MA, Prowse KR, et al: Specific association of human 
telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015. 
19. Norton JC, Holt SE, Wright WE, et al: Enhanced detection of human telomerase 
activity. DNA Cell Biol 1998; 17: 217-219. 
20. Kim NW, Wu F: Advances in quantification and characterization of telomerase 
activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res 
1997; 25: 2595-2597. 
21. Herbert BS, Hochreiter AE, Wright WE, et al: Nonradioactive detection of 
telomerase activity using the telomeric repeat amplification protocol. Nat Protoc 
2006; 1: 1583-1590. 
22. Krupp G, Kuhne K, Tamm S, et al: Molecular basis of artifacts in the detection of 
telomerase activity and a modified primer for a more robust 'TRAP' assay. Nucleic 
Acids Res 1997; 25: 919-921. 
23. Pinheiro LB, Coleman VA, Hindson CM, et al: Evaluation of a droplet digital 
polymerase chain reaction format for DNA copy number quantification. Anal Chem 
  48 
2012; 84: 1003-1011. 
24. Hindson BJ, Ness KD, Masquelier DA, et al: High-throughput droplet digital PCR 
system for absolute quantitation of DNA copy number. Anal Chem 2011; 83: 
8604-8610. 
25. Dube S, Qin J, Ramakrishnan R: Mathematical analysis of copy number variation in 
a DNA sample using digital PCR on a nanofluidic device. PLoS One 2008; 3: 
e2876. 
26. Ludlow AT, Robin JD, Sayed M, et al: Quantitative telomerase enzyme activity 
determination using droplet digital PCR with single cell resolution. Nucleic Acids 
Res 2014; 42: e104. 
27. Brugge WR, Lewandrowski K, Lee-Lewandrowski E, et al: Diagnosis of pancreatic 
cystic neoplasms: a report of the cooperative pancreatic cyst study. 
Gastroenterology 2004; 126: 1330-1336. 
28. Armbruster DA, Pry T: Limit of blank, limit of detection and limit of quantitation. 
Clin Biochem Rev 2008; 29 Suppl 1: S49-52. 
29. Huang S, Wang T, Yang M: The evaluation of statistical methods for estimating the 
lower limit of detection. Assay Drug Dev Technol 2013; 11: 35-43. 
30. Sato N, Maehara N, Mizumoto K, et al: Telomerase activity of cultured human 
pancreatic carcinoma cell lines correlates with their potential for migration and 
invasion. Cancer 2001; 91: 496-504. 
31. Ouyang H, Mou L, Luk C, et al: Immortal human pancreatic duct epithelial cell lines 
with near normal genotype and phenotype. Am J Pathol 2000; 157: 1623-1631. 
32. Jakupciak JP: Real-time telomerase activity measurements for detection of cancer. 
  49 
Expert Rev Mol Diagn 2005; 5: 745-753. 
33. Shim WY, Park KH, Jeung HC, et al: Quantitative detection of telomerase activity 
by real-time TRAP assay in the body fluids of cancer patients. Int J Mol Med 2005; 
16: 857-863. 
34. Hou M, Xu D, Bjorkholm M, et al: Real-time quantitative telomeric repeat 
amplification protocol assay for the detection of telomerase activity. Clin Chem 
2001; 47: 519-524. 
35. Wege H, Chui MS, Le HT, et al: SYBR Green real-time telomeric repeat 
amplification protocol for the rapid quantification of telomerase activity. Nucleic 
Acids Res 2003; 31: E3-3. 
36. Trypsteen W, Vynck M, De Neve J, et al: ddpcRquant: threshold determination for 
single channel droplet digital PCR experiments. Anal Bioanal Chem 2015; 407: 
5827-5834. 
37. McDermott GP, Do D, Litterst CM, et al: Multiplexed target detection using 
DNA-binding dye chemistry in droplet digital PCR. Anal Chem 2013; 85: 
11619-11627. 
38. Hoffman RL, Gates JL, Kochman ML, et al: Analysis of cyst size and tumor 
markers in the management of pancreatic cysts: support for the original Sendai 
criteria. J Am Coll Surg 2015; 220: 1087-1095. 
39. Wang J, Paris PL, Chen J, et al: Next generation sequencing of pancreatic cyst fluid 
microRNAs from low grade-benign and high grade-invasive lesions. Cancer Lett 
2015; 356: 404-409. 
40. Amato E, Molin MD, Mafficini A, et al: Targeted next-generation sequencing of 
  50 
cancer genes dissects the molecular profiles of intraductal papillary neoplasms of 
the pancreas. J Pathol 2014; 233: 217-227. 
41. Matthaei H, Wylie D, Lloyd MB, et al: miRNA biomarkers in cyst fluid augment the 
diagnosis and management of pancreatic cysts. Clin Cancer Res 2012; 18: 
4713-4724. 
42. Springer S, Wang Y, Molin MD, et al: A Combination of Molecular Markers and 
Clinical Features Improve the Classification of Pancreatic Cysts. Gastroenterology 
2015. 
43. Wu J, Matthaei H, Maitra A, et al: Recurrent GNAS mutations define an unexpected 
pathway for pancreatic cyst development. Sci Transl Med 2011; 3: 92ra66. 
44. Maker AV, Katabi N, Qin LX, et al: Cyst fluid interleukin-1beta (IL1beta) levels 
predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the 
pancreas. Clin Cancer Res 2011; 17: 1502-1508. 
45. Kosmahl M, Pauser U, Anlauf M, et al: Pancreatic ductal adenocarcinomas with 
cystic features: neither rare nor uniform. Mod Pathol 2005; 18: 1157-1164. 
46. Heaphy CM, Subhawong AP, Hong SM, et al: Prevalence of the alternative 
lengthening of telomeres telomere maintenance mechanism in human cancer 
subtypes. Am J Pathol 2011; 179: 1608-1615. 
 
  51 
Figure and table legends 
 
Figure 1. Experimental study workflow of the gel-TRAP and dd-TRAP assay. 
 
Figure 2. (A) Representative result of the dd-TRAP analysis using MIA PaCa-2 pancreatic 
cancer cell line. (B) The actual accepted droplets in each sample shown in (A), showing 
approximately 16,000–19,000 droplets. (C) Target concentration (copies/µL; PCR scale) 
using Poisson statistics in each sample shown in (A), showing the significant lower 
telomerase products in negative control wells. (D) Gel-imaging after the electrophoresis of 
amplified telomerase products using the dd-TRAP assay (left side) and the gel-TRAP assay 
(right side). Following PCR reaction, droplets containing PCR products were treated with 
phenol/chloroform and extracted the amplified DNA from droplets. 
HI, heat inactivation; Rn, RNase A treatment; NTC-LB, non template control lysis buffer; 
IC, internal control. 
 
Figure 3. (A) Representative electrophoresis gel image of the gel-TRAP assay using the 
serial dilution extracts from MIA PaCa-2 cells. (B) Relative intensity as telomerase activity 
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after the densitometric analysis. (C) 1-D plot graphics of the dd-TRAP assay using the 
same serial dilution as shown in the gel-TRAP assay. (D) Concentration of telomerase 
products with Poisson 95% confidence limits. (E) Illustration of the relationship between 
LOB and LOD. For a blank sample of NTC-LB (red line), 95% of its quantification results 
(α = 0.05) fall at or below LOB. For a sample with low concentration of cell extract (blue 
line) whose concentration equals to LOD, 95% of tis quantification results (β = 0.05) 
exceed the LOB. (F) Correlation analysis of the gel-TRAP assay and the dd-TRAP assay 
using serial diluted samples from MIA PaCa-2 cell extracts. R2 means coefficient of 
determination. 
IC, internal control; NTC-LB, non template control lysis buffer; LOB, limit of blank; LOD, 
limit of detection. 
 
Figure 4. (A, B) Representative gel image and 1-D plot graphic of the gel-TRAP assay (A) 
and the dd-TRAP assay (B) using pancreatic cancer cell lines. (C) Concentration of 
telomerase products of the dd-TRAP assay. Error bar indicates Poisson 95% confidence 
limits. (D) Correlation analysis of gel-TRAP assay and dd-TRAP assay using 11 pancreatic 
caner cell lines including HPDE immortalized pancreatic ductal epithelial cell line. Relative 
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telomerase activity was calculated by MIA PaCa-2 cells was set 1.0 for reference. R2 means 
coefficient of determination. 
N, nontemplate control lysis buffer. 
 
Figure 5. Schema of sample selection process. 
 
Figure 6. (A) Protein concentration after the three repeats of protein extraction from the 
different number of MiA PaCa-2 cells. (B) The repeat number of protein extraction from 
the same precipitates in each original cyst fluid sample until lysed protein was undetectable. 
 
Figure 7. Comparison of cell free telomerase activity in supernatant and that in precipitate 
from the same original cyst fluid. Serous cyst fluid samples were labeled as “S” and 
mucinous ones as “M”. 
 
Figure 8. Linear correlation between the loading amount of cell extract and the amplified 
telomerase product using dd-TRAP assay. 1-D graphics stand for the actual concentration 
of telomerase activity in each loading protein amount. R2 means coefficient of 
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determination. 
 
Figure 9. Coefficient of variation of telomerase activity measurements. The mean value of 
telomerase activity measured in three independent dd-TRAP assays measured on four 
different days. The horizontal bar indicates the mean value for each day. % CV means 
coefficient of variants calculated by the following formula: Standard deviation / Mean 
value × 100 (%).  
CV, coefficient of variation. 
 
Figure 10. Telomerase activity in samples sratified according to their thaw and freeze cycle 
and year of sample collection in each diagnostic subgroup. The longer horizontal bar 
represents the median value and shorter ones represents values of the 75th and 25th 
percentiles, respectively. **P < 0.01, ***P < 0.001 
N.S., not significant. 
 
Figure 11. (A) Absolute quantification of telomerase activity per microliter of original cyst 
fluid samples among 84 samples that had not undergone any prior thawing. The longer 
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horizontal bar represents the median value and shorter ones represents values of the 75th 
and 25th percentiles, respectively. (B) Comparison of telomerase activity of IPMN cases 
classified by their surgical indication (invasive cancer and HGD vs. IGD and LGD) and 
SCN cases. (C) Telomerase activity levels per microliter of cyst fluid samples in each 
group. (D, E) ROC curve analysis for the diagnostic accuracy of telomerase activity in 
predicting malignancy among all 84 cases (D) and 58 IPMN cases (E). 
IQR, interquartile range; SE, standard error; CI, confidence interval. N.S., not significant. 
*P < 0.05, ***P < 0.001. 
 
Figure 12. Measurement of telomerase activity in 100 samples that had undergone multiple 
freeze/thaws. (A) Absolute quantification of telomerase activity per microliter of original 
cyst fluid samples. The longer horizontal bar represents the median value and shorter ones 
represents values of the 75th and 25th percentiles, respectively. (B) ROC curve analysis for 
the diagnostic accuracy of telomerase activity in predicting HGD/invasive cancer (C) 
Comparison of telomerase activity in IPMN cases classified by their surgical indication 
(invasive cancer and HGD vs. IGD and LGD) and SCN cases. (D) ROC curve analysis for 
the diagnostic accuracy of telomerase activity in predicting IPMN with HGD/invasive 
cancer. 
SE, standard error; CI, confidence interval. N.S., not significant. 
***P < 0.001. 
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Figure 13. (A) Measurement of telomerase activity using all 184 samples without 
accounting for sample thawing and re-freezing. The longer horizontal bar represents the 
median value and shorter ones represents values of the 75th and 25th percentiles, 
respectively. (B) ROC curve analysis for the diagnostic accuracy of telomerase activity in 
predicting HGD/invasive cancer (C) Comparison of telomerase activity in IPMN cases 
classified by the surgical indication (invasive cancer and HGD vs. IGD and LGD) and SCN 
cases. (D) ROC curve analysis for the diagnostic accuracy of telomerase activity in 
predicting IPMN with HGD/invasive cancer. 
SE, standard error; CI, confidence interval. N.S., not significant. 
***P < 0.001. 
 
Figure 14. Telomerase activity of SCN cases classified into cyst fluid color. The longer 
horizontal bar represents the median value and shorter ones represents values of the 75th 
and 25th percentiles, respectively.  
*P < 0.05. 
 
Figure 15. Pathological diagnosis of pancreatic cystic tumors in each risk group. 
 
Table 1. Clinical and imaging features of pancreatic cystic tumor for the aseeement of 
preoperative risk of malignancy. 
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Table 2. Patient and cyst fluid characteristics for all 184 cases. 
PD, pancreaticoduodenectomy; DP, distal pancreatectomy; TP, total pancreatectomy. MP, middle 
pancreatectomy;  
*Histological grade of PanNET was diagnosed on the basis of WHO 2010 criteria. 
 
Table 3. Length of storage and freeze and thaw repeats of surgically aspirated pancreatic cyst fluid 
samples. 
 
Table 4. Patient and cyst fluid characteristics for 84 cases without prior thaw/freezing. 
PD, pancreaticoduodenectomy; DP, distal pancreatectomy; TP, total pancreatectomy. MP, middle 
pancreatectomy;  
*Histological grade of PanNET was diagnosed on the basis of WHO 2010 criteria. 
 
Table 5. Diagnostic performance of telomerase activity comparing to the multiple imaging 
and clinical factors. 
CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value 
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Table 6. Diagnostic performance of combination assay for predicting invasive cancer or 
high-grade dysplasia among 84 cases without prior freeze/thawing 
 
Table 7. Univariate and multivariate analyses of malignant predictive factors for pancreatic 
cystic tumor. Bold line indicates the statistical significance. 
OR, odds ratio; CI, confidence interval. 
 
Table 8. Diagnostic performance of telomerase activity in stratified subgroup by the risk of 
malignancy. 
*Value of telomerase activity in pancreatic cyst fluid (copies/µL of cyst fluid). 
TP, true positive; FN, false negative; FP, false positive; TN, true negative; CI, confidence 
interval; PPV, positive predictive value; NPV, negative predictive value. 
 
Table 9. List of matched cases with endoscopically and surgically aspirated cyst fluid 
samples. 
*Copies/µL of original cyst fluid 
EUS, Endoscopic ultrasonography; DP, diatal pancreatectomy; PD, 
pancreaticoduodenectomy 
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Table 1. Clinical and imaging features of pancreatic cystic tumor for the aseeement of preoperative 
risk of malignancy. 
High-risk stigmata   
 
Obstructive jaundice with cystic lesion 
 
Enhancing solid component within cyst 
 MPD size of ≥ 10 mm 
Worrisome features 
 
 
Cyst size of ≥ 30 mm 
 
Thickened/enhancing cyst walls 
 
MPD size of ≥ 5 mm 
 
Non-enhanced mural nodule 
 
Abrupt change in the MPD with distal pancreatic atrophy 
 
Pancreatitis 
 Lymphadenopathy 
 
Table 2. Patient and cyst fluid characteristics for all 184 cases. 
Characteristics Total (n = 184) IPMN (n = 118) MCN (n = 12) SCN (n = 45) PanNET (n = 1) Pseudocyst (n = 8) 
Male/Female (n) 83/101 65/53 0/12 13/32 0/1 5/3 
Age (median, range), year 67 (27–87) 68 (42–87) 47 (28–65) 60 (30–85) 54 57 (27–82) 
Symptoms 
      
 
Abdominal pain 42 21 7 12 0 2 
 
Pancreatitis 10 10 0 0 0 0 
 
Jaundice 4 4 0 0 0 0 
 
Weight loss 1 1 0 0 0 0 
 
Appetite loss 2 1 0 1 0 0 
 
Nausea 2 1 0 1 0 0 
Cyst location 
      
 
Head and uncinate/ body and tail 98/86 74/44 0/12 19/26 1/0 4/4 
Cyst size, median (range), cm 3.0 (0.5–20.0) 2.5 (0.5–10.0) 4.7 (1.6–20.0) 4.0 (1.5–13.5) 5 3.4 (1.3–11.5) 
Mural nodule 
      
 
Absent/Present 126/58 77/41 11/1 33/12 0/1 5/3 
Communication with MPD 
      
 
Absent/Present 110/74 51/67 12/0 38/7 1/0 8/0 
Dilatation of MPD ≥10mm 
      
 
Absent/Present 159/25 93/25 12/0 45/0 1/0 8/0 
Dilatation of MPD ≥5mm 
      
 
Absent/Present 131/53 68/50 12/0 43/2 1/0 7/1 
CT/MRI findings  
      
 
Worrisome features 118 61 11 37 1 8 
 
High-risk stigmata 39 37 0 2 0 0 
 
no risk 27 20 1 6 0 0 
Table 2. Patient and cyst fluid characteristics for all 184 cases (Cont’d) 
Characteristics Total (n = 184) IPMN (n = 118) MCN (n = 12) SCN (n = 45) PanNET (n = 1) Pseudocyst (n = 8) 
Cyst fluid color 
      
 
Bloody/Sero-bloody/Brown/Straw/Clear 28/72/37/5/42 18/50/17/3/30 0/1/4/0/7 10/17/14/0/4 0/1/0/0/0 0/3/2/2/1 
Cyst fluid appearance 
      
 
Serous/Mucinous 103/81 49/69 10/2 43/2 0/1 7/1 
Original cyst volume (median, range), µL 250 (40–1000) 200 (40–1000) 350 (200–600) 400 (150–1000) 200 50 (50–1000) 
EUS-FNA (n = 76) 
      
 
Non-diagnostic 15 7 2 6 0 0 
 
Benign/Atypia/Cancer 32/16/13 18/15/13 5/1/0 7/0/0 0/0/0 2/0/0 
Cyst fluid CEA (≥192 ng/mL), n = 44 
      
 
<192 ng/mL/≥192 ng/mL 30/14 13/11 4/3 12/0 0/0 1/0 
Operative procedure 
      
 
PD/DP/TP/MP 97/81/5/1 73/40/4/1 0/12/0/0 19/26/0/0 0/0/1/0 5/3/0 
Morphological duct type 
      
 
Main duct/Branch duct 
 
29/89 
    Grade of dysplasia 
        LGD/IGD/HGD/Cancer 20/59/31/20 12/58/28/20 8/1/3/0   NET G2*   
IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm; SCN, serous cystic neoplasm; PanNET, pancreatic neuroendocrine tumor; 
MPD, main pancreatic duct; CT, computed tomography; MRI, magnetic resonance imaging; EUS-FNA, endoscopic ultrasonography-fine needle aspiration, 
CEA, carcinoembryonic antigen; PD, pancreaticoduodenectomy; DP, distal pancreatectomy; TP, total pancreatectomy. MP, middle pancreatectomy; HGD, high 
grade dysplasia; IGD, intermediate grade dysplasia; LGD, low grade dysplasia. 
*Histological grade of PanNET was diagnosed on the basis of WHO 2010 criteria. 
Table 3. Length of storage and freeze and thaw repeats of surgically aspirated pancreatic cyst fluid 
samples. 
Findings Total (n = 184) 
Year of sample collection 
  
 
2008 3 
 
 
2009 1 
 
 
2010 17 
 
 
2011 31 
 
 
2012 27 
 
 
2013 31 
 
 
2014 42 
 
 
2015 32 
 Freeze and thaw repeat(s) 
  
 
1 84 
 
 
2 93 
  3 7  
 
Table 4. Patient and cyst fluid characteristics for 84 cases without prior thaw/freezing. 
Characteristics Total (n = 84) IPMN (n = 58) SCN (n = 20) PanNET (n = 1) Pseudocyst (n = 5) 
Male/Female (n) 45/39 35/23 6/14 0/1 4/1 
Age (median, range), year 68 (37–87) 68 (42–87) 64 (37–77) 54 73 (54–82) 
Symptoms 
     
 
Abdominal pain 16 10 4 0 2 
 
Pancreatitis 7 7 0 0 0 
 
Jaundice 1 1 0 0 0 
 
Nausea 1 0 1 0 0 
Cyst location 
     
 
Head and uncinate/ body and tail 46/38 33/25 10/10 1/0 2/3 
Cyst size, median (range), cm 2.5 (0.5–11.5) 2.3 (0.5–9.0) 3.2 (1.5–10.0) 5 3.8 (2.5–11.5) 
Mural nodule 
     
 
Absent/Present 50/34 33/25 13/7 0/1 4/1 
Communication with MPD 
     
 
Absent/Present 43/41 22/36 15/5 1/0 5/0 
Dilatation of MPD ≥10mm 
     
 
Absent/Present 71/13 45/13 20/0 1/0 5/0 
Dilatation of MPD ≥5mm 
     
 
Absent/Present 56/28 32/26 19/1 1/0 4/1 
CT/MRI findings  
     
 
Worrisome features 50 31 13 1 5 
 
High-risk stigmata 19 17 2 0 0 
 
no risk 15 10 5 0 0 
Cyst fluid color 
     
 
Bloody/Sero-bloody/Brown/Straw/Clear 19/36/9/5/15 14/24/4/3/13 5/10/3/0/2 0/1/0/0/0 0/1/2/2/0 
Table 4. Patient and cyst fluid characteristics for 84 cases without prior thaw/freezing (Cont’d) 
Characteristics Total (n = 84) IPMN (n = 58) SCN (n = 20) PanNET (n = 1) Pseudocyst (n = 5) 
Cyst fluid appearance 
     
 
Serous/Mucinous 39/45 17/41 18/2 0/1 4/1 
Original cyst volume (median, range), µL 150 (40–1000) 103 (40–800) 300 (150–1000) 200 50 (50–200) 
EUS-FNA (n = 30) 
     
 
Non-diagnostic 4 1 3 0 0 
 
Benign/Atypia/Cancer 11/8/7 8/8/7 3/0/0 0/0/0 0/0/0 
Cyst fluid CEA (≥192 ng/mL), n = 17 
     
 
<192 ng/mL/≥192 ng/mL 12/5 6/5 6/0 0/0 0/0 
Operative procedure 
     
 
PD/DP/TP/MP 47/34/2/1 34/22/1/1 11/9/0/0 0/0/1/0 2/3/0/0 
Morphological duct type 
     
 
Main duct/Branch duct 
 
14/44 
   Grade of dysplasia 
       LGD/IGD/HGD/Cancer  2/32/17/7   NET G2   
IPMN, intraductal papillary mucinous neoplasm; SCN, serous cystic neoplasm; PanNET, pancreatic neuroendocrine tumor; MPD, main pancreatic duct; CT, 
computed tomography; MRI, magnetic resonance imaging; EUS-FNA, endoscopic ultrasonography-fine needle aspiration, CEA, carcinoembryonic antigen; PD, 
pancreaticoduodenectomy; DP, distal pancreatectomy; TP, total pancreatectomy. MP, middle pancreatectomy; HGD, high grade dysplasia; IGD, intermediate 
grade dysplasia; LGD, low grade dysplasia. 
*Histological grade of PanNET was diagnosed on the basis of WHO 2010 criteria. 
Table 5. Diagnostic performance of telomerase activity comparing to the multiple imaging and clinical factors. 
Findings Cut-off 
Sensitivity (%) Specificity (%) Accuracy 
(%) 
PPV 
(%) 
NPV 
(%) (95% CI) (95% CI) 
All cases (n = 84) 
        
 
Cyst appearance Mucinous 87.5 (67.6–97.3) 60.0 (46.5–72.4) 67.9 46.7 92.3 
 
Cyst size ≥30 mm 41.7 (22.2–63.4) 61.7 (48.2–73.9) 56.0 30.3 72.6 
 
MPD dilatation  ≥10 mm 33.3 (15.6–55.3) 91.7 (81.6–97.2) 75.0 61.5 77.5 
 
MPD dilatation ≥5 mm 66.7 (44.7–84.4) 80.0 (67.7–89.2) 76.2 57.1 85.7 
 
Mural nodule Present 62.5 (40.6–81.2) 68.3 (55.0–79.7) 66.7 44.1 82.0 
 
Telomerase activity ≥730 copies/µL cyst fluid 83.3 (62.6–95.3) 90.0 (79.5–96.2) 88.1 76.9 93.1 
IPMN cases (n = 58) 
        
 
Cyst appearance Mucinous 87.5 (67.6–97.3) 41.2 (24.6–59.3) 60.3 51.2 82.4 
 
Cyst size ≥30 mm 41.7 (22.2–63.4) 70.6 (52.5–84.9) 58.6 50.0 63.2 
 
MPD dilatation  ≥10 mm 33.3 (15.6–55.3) 85.3 (68.9–95.1) 63.8 61.5 64.4 
 
MPD dilatation ≥5 mm 66.7 (44.7–84.4) 70.6 (52.5–84.9) 69.0 61.5 75.0 
 
Mural nodule Present 62.5 (40.6–81.2) 70.6 (52.5–84.9) 67.2 60.0 72.7 
 Telomerase activity ≥730 copies/µL cyst fluid 83.3 (62.6–95.3) 82.4 (65.5–93.2) 82.8 76.9 87.5 
MPD, main pancreatic duct; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value 
 
Table 6. Diagnostic performance of combination assay for predicting invasive cancer or high-grade 
dysplasia among 84 cases without prior freeze/thawing. 
Any of these present 
Sensitivity (%) Specificity (%) Accuracy (%) 
Imaging findings 
Telomerase activity 
(copies/µL cyst fluid) 
Any of these 
present 
MPD ≥10 mm 
None 33.3 91.7 75.0 
≥730 87.5 83.3 84.5 
≥814 87.5 85.0 85.7 
Mural nodule 
None 62.5 68.3 66.7 
≥730 95.8 66.7 75.0 
MPD ≥10 mm None 70.8 63.3 65.5 
Mural nodule ≥730 100.0 61.7 72.6 
All of these  
present 
MPD ≥10 mm None 25.0 96.7 76.2 
Mural nodule ≥730 50.0 90.0 78.6 
MPD, main pancreatic duct 
Table 7. Univariate and multivariate analyses of malignant predictive factors for pancreatic cystic tumor. 
Variable 
Cancer, HGD 
(n = 24) 
Others  
(n = 60) 
Univariate 
P 
      Multivariate   
  OR   95% CI P 
Age 
          
 
<68 11 
 
30 
 
0.7300 
     
 
≥68 13 
 
30 
      Sex 
          
 
Female 8 
 
31 
 
0.1280 
     
 
Male 16 
 
29 
      Fluid appearance 
          
 
Serous 3 
 
36 
 
<0.0001 
 
1.000 
   
 
Mucinous 21 
 
24 
  
0.727 
 
0.034–6.405 0.787 
Cyst size 
          
 
<30 mm 14 
 
37 
 
0.7775 
     
 
≥30 mm 10 
 
23 
      Cyst location 
          
 
Body and tail 8 
 
30 
 
0.1656 
     
 
Head 16 
 
30 
      MPD dilatation 
          
 
<5 mm 8 
 
48 
 
<0.0001 
 
1.000 
   
 
≥5 mm 16 
 
12 
  
0.931 
 
0.137–5.059 0.936 
MPD communication 
          
 
Absent 5 
 
38 
 
0.0004 
 
1.000 
   
 
Present 19 
 
22 
  
3.242 
 
0.630–18.057 0.157 
Mural nodule 
          
 
Absent 9 
 
41 
 
0.0093 
 
1.000 
   
 
Present 15 
 
19 
  
1.278 
 
0.273–5.364 0.743 
Telomerase activity 
          
 
<730 copies/µL (cyst fluid) 4 
 
54 
 
<0.0001 
 
1.000 
    ≥730 copies/µL (cyst fluid) 20  6    41.488  4.897–992.730 0.0002 
HGD, high grade dysplasia; OR, odds ratio; CI, confidence interval; MPD, main pancreatic duct. 
Table 8. Diagnostic performance of telomerase activity in stratified subgroup by the risk of malignancy. 
Subgroup n AUC Cut off* TP FN FP TN 
Sensitivity (%)  
(95% CI) 
Specificity (%)  
(95% CI) 
Accuracy 
(%) 
PPV 
(%) 
NPV 
(%) 
All cases (n = 84) 
               
 
High-risk stigmata 19 0.784 730 
 
8 3 1 7 72.7 (39.0–94.0) 87.5 (47.4–99.7) 78.9 88.9 70.0 
 
Worrisome features 50 0.927 730 
 
12 1 5 32 92.3 (64.0–99.8) 86.5 (71.2–95.5) 88.0 70.6 97.0 
IPMN cases (n = 58) 
 
 
  
    
       
 
High-risk stigmata 17 0.758 730 
 
8 3 1 5 72.7 (39.0–94.0) 83.3 (35.9–99.6) 76.5 88.9 62.5 
 Worrisome features 31 0.876 730  12 1 5 13 92.3 (64.0–99.8) 72.2 (46.5–90.3) 83.9 70.6 92.9 
* Value of telomerase activity in pancreatic cyst fluid (copies/µL of cyst fluid). 
AUC, area under the curve; TP, true positive; FN, false negative; FP, false positive; TN, true negative; PPV, positive predictive value; NPV, negative predictive 
value. 
Table 9. List of matched cases with endoscopically and surgically aspirated cyst fluid samples. 
Case 
No. 
Age Sex 
Tumor 
location 
Endoscopically aspirated cyst fluid 
From EUS to 
Ope. (month) 
Operative 
Procedures 
Surgically aspirated cyst fluid 
CEA 
(ng/mL) 
Amylase 
(U/L) 
Telomerase 
activity*  
Histocytological 
diagnosis  
Telomerase 
activity* 
Histological 
diagnosis  
1 54 F Tail 61.6 
 
99 
 
0.00 
 
Non-diagnostic  8.9 DP 0.00 
 
Pseudocyst 
2 73 F Body <1.0 
 
31 
 
2.41 
 
Non-diagnostic 14.3 DP 2.36 
 
SCN 
3 78 M Head 168.0   N/A   20.29   Benign  9.3 PD 13118.29   IPMN with HGD 
*Copies/µL of original cyst fluid 
EUS, Endoscopic ultrasonography; DP, diatal pancreatectomy; PD, pancreaticoduodenectomy 
